Skip to content

Visionary Ventures

Life sciences venture capital fund investing in ophthalmology and medical aesthetics.

HOME
OPHTHALMOLOGY FUND
Visionary KOLs
TEAM
- Investment Committee
- Fund Management
PORTFOLIO
NEWS
CONTACT
INVESTOR LOGIN

Fund Menu

Search:

HOME
OPHTHALMOLOGY FUND
Visionary KOLs
TEAM
- Investment Committee
- Fund Management
PORTFOLIO
NEWS
CONTACT
INVESTOR LOGIN

Orasis CEO, Elad Kedar, Interviewed at OIS and AAO

Video interview with Orasis CEO, Elad Kedar discussing the presbyopia market and the Orasis product.

Click here to view the interview

Search:

Recent Posts

Orasis Pharmaceuticals Completes $78 Million Financing to Support Commercial Launch of Qlosi™
October 9, 2024
Iantrek Announces Publication of Results of its Bio-interventional Uveoscleral Outflow Technology in Patients with Open-Angle Glaucoma
September 13, 2024
ONL Therapeutics Closes $65 Million In Oversubscribed Series D Financing
September 13, 2024

Categories

Acquisition(2)
Aurion(4)
IanTECH(2)
Iantrek(2)
IPO(2)
License Deal(1)
News(68)
ONL(3)
Orasis(17)
Pelage(2)
Re-Vana(4)
RxSight(2)
Surface(1)
Sydnexis(3)
Tarsus(7)
Tear Film(4)
TearClear(8)
Visionary(9)

Archives

Visionary Ventures

Visionary Ventures is a venture capital fund that invests in life sciences and the future of ophthalmology and medical aesthetics. We are an opportunistic venture fund that invests in early and late stages of a company's growth, from early-stage Series A rounds in clinical trials to late-stage rounds in commercialization. Our target investment range is $5M to $15M.

Contact Us

Visionary Ventures
620 Newport Center Drive, Suite 650
Newport Beach CA 92660
info@visionaryvc.com

Home
Ophthalmology
Team
Portfolio
News
Contact
Investor Portal

Footer Menu

© 2019 Visionary Ventures. All Rights Reserved.